194 related articles for article (PubMed ID: 38001170)
1. Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study.
Zaliova M; Zuna J; Winkowska L; Janotova I; Skorepova J; Lukes J; Meyer C; Marschalek R; Novak Z; Domansky J; Stary J; Sramkova L; Trka J
Leukemia; 2024 Jan; 38(1):21-30. PubMed ID: 38001170
[TBL] [Abstract][Full Text] [Related]
2. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
3. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
4. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
Aitken MJL; Ravandi F; Patel KP; Short NJ
J Hematol Oncol; 2021 Sep; 14(1):137. PubMed ID: 34479626
[TBL] [Abstract][Full Text] [Related]
6. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.
Blackmon AL; Hourigan CS
Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547
[TBL] [Abstract][Full Text] [Related]
7. Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.
Ganzel C; Sun Z; Baslan T; Zhang Y; Gönen M; Abdel-Wahab OI; Racevskis J; Garrett-Bakelman F; Lowe SW; Fernandez HF; Ketterling R; Luger SM; Litzow M; Lazarus HM; Rowe JM; Tallman MS; Levine RL; Paietta E
Leuk Res; 2022 Dec; 123():106971. PubMed ID: 36332294
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
9. Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them.
Li SQ; Chen M; Huang XY; Wang H; Chang YJ
Expert Rev Hematol; 2023; 16(12):981-990. PubMed ID: 37978882
[TBL] [Abstract][Full Text] [Related]
10. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of measurable residual disease based on multiparameter flow cytometry in childhood acute myeloid leukemia.
Huo Y; Guan XM; Dou Y; Wen XH; Guo YX; Shen YL; An XZ; Yu J
Zhongguo Dang Dai Er Ke Za Zhi; 2021 Nov; 23(11):1111-1118. PubMed ID: 34753542
[TBL] [Abstract][Full Text] [Related]
12. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
13. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients.
Sun Y; Zhu G; Zhong H
Eur J Haematol; 2024 Jun; 112(6):870-878. PubMed ID: 38342613
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.
van der Velden VH; van der Sluijs-Geling A; Gibson BE; te Marvelde JG; Hoogeveen PG; Hop WC; Wheatley K; Bierings MB; Schuurhuis GJ; de Graaf SS; van Wering ER; van Dongen JJ
Leukemia; 2010 Sep; 24(9):1599-606. PubMed ID: 20668473
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
17. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Xiao W; Petrova-Drus K; Roshal M
Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
[TBL] [Abstract][Full Text] [Related]
18. Time point-dependent concordance and prognostic significance of flow cytometry and real time quantitative PCR for measurable/minimal residual disease detection in acute myeloid leukemia with t(8;21)(q22;q22.1).
Shang L; Cai X; Sun W; Cheng Q; Mi Y
Cytometry B Clin Cytom; 2022 Jan; 102(1):34-43. PubMed ID: 34232569
[TBL] [Abstract][Full Text] [Related]
19. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML).
Patkar N; Kakirde C; Shaikh AF; Salve R; Bhanshe P; Chatterjee G; Rajpal S; Joshi S; Chaudhary S; Kodgule R; Ghoghale S; Deshpande N; Shetty D; Khizer SH; Jain H; Bagal B; Menon H; Khattry N; Sengar M; Tembhare P; Subramanian P; Gujral S
Leukemia; 2021 May; 35(5):1392-1404. PubMed ID: 33558666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
